Newsletter Tool

Today's Rundown

The top 10 drugs losing US exclusivity in 2022
BioNTech-Regeneron add 3rd tumor type to partnership testing cancer vaccines with Libtayo
ViVE 2022: How UnitedHealth, Humana are thinking about 'techquity'
On Medtronic's tail, Axonics scores FDA nod for 15-year neurostim implant for incontinence
Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters
ViVE 2022: Google Health expands AI capabilities of Care Studio to organize patient data
GV-backed DNAnexus snags $200M to build out genomic data analytics platform
Novartis eyes next-gen AAV gene therapies in $1.75B Voyager biobucks pact
Sanofi deploying $1B to turn France into 'pioneer mRNA nation'
Healthcare sector adds a hefty 63,500 jobs in February but still lags pre-pandemic employment
Sherlock Biosciences unearths $80M to bring CRISPR-based tests into the home
As Eli Lilly grows beyond Research Triangle Park, biopharmas big and small are tapping North Carolina's 'limitless' potential

Featured Story

The top 10 drugs losing US exclusivity in 2022

By Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner

With AbbVie’s megablockbuster Humira set to face an onslaught of biosimilars next year, industry watchers have long circled 2023 as the year of the major pharma patent cliff. But this year’s slate of top losses of exclusivity covers a hefty slate of brands worth more than $17 billion in annual sales.

BioNTech-Regeneron add 3rd tumor type to partnership testing cancer vaccines with Libtayo

By Max Bayer

BioNTech wants to run it back with Regeneron, extending a partnership first announced in 2020 to combine a cancer vaccine with the approved treatment Libtayo in the clinic, this time for advanced non-small cell lung cancer.

ViVE 2022: How UnitedHealth, Humana are thinking about 'techquity'

By Paige Minemyer

MIAMI—Two key topics have dominated the industry conversation amid the COVID-19 pandemic: health equity and the role of technology. But these are not distinct entities, insurance executives said Monday at the inaugural ViVE Conference in Miami.

On Medtronic's tail, Axonics scores FDA nod for 15-year neurostim implant for incontinence

By Andrea Park

The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—and Medtronic and Axonics Modulation Technologies are aiming for a photo finish.

Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters

By Eric Sagonowsky

When Gilead Sciences picked up Immunomedics and the breast cancer drug Trodelvy for $21 billion a couple years back, the company billed the buyout as a major expansion into oncology. Now, the California-based drugmaker is laying off more than 100 staffers based out of the former Immunomedics headquarters as it gears up for change in New Jersey.

ViVE 2022: Google Health expands AI capabilities of Care Studio to organize patient data

By Heather Landi

During the ViVE 2022 conference, Google Health executive Paul Muret detailed how Care Studio is using its tech expertise to unify patient data for clinicians.

GV-backed DNAnexus snags $200M to build out genomic data analytics platform

By Andrea Park

So far, according to DNAnexus, the platform is used by seven of the world’s top 10 pharmaceutical companies and eight of the 10 biggest diagnostics developers—to single out just a few of its more than 12,000 total users located in four dozen countries across the globe.

Novartis eyes next-gen AAV gene therapies in $1.75B Voyager biobucks pact

By Annalee Armstrong

In Novartis’ perennial hunt for innovative therapies to bring under its wing, improving on gene therapy has always been kept top of mind. And the Swiss pharma continues to do just that thanks to a new biobucks deal with Voyager Therapeutics worth up to $1.75 billion.

Sanofi deploying $1B to turn France into 'pioneer mRNA nation'

By Kyle LaHucik

Sanofi will invest about $1 billion in its home country to beef up mRNA R&D and vaccines production in France. The move is part of the Big Pharma's broader $2.2 billion mRNA commitment revealed last summer.

Healthcare sector adds a hefty 63,500 jobs in February but still lags pre-pandemic employment

By Dave Muoio

Healthcare employers saw their strongest jobs recovery in months, with ambulatory services, in particular, adding thousands of workers to their payrolls.

Sherlock Biosciences unearths $80M to bring CRISPR-based tests into the home

By Conor Hale

Since its 2019 launch, the former Fierce 15 winner has secured an FDA authorization for a COVID-19 test powered by the gene editing method.

As Eli Lilly grows beyond Research Triangle Park, biopharmas big and small are tapping North Carolina's 'limitless' potential

By Fraiser Kansteiner

There are 775 or more life science companies in the state of North Carolina that directly employ about 68,000 people, Doug Edgeton, president and CEO of the North Carolina Biotechnology Center, said in an interview.

PM Tracker